Kezdőlap・Részvénylista・ImmunityBio Inc

ImmunityBio Inc

Lezárt

SzektorEgészségügy

7.42 2.34

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

7.18

Maximum

7.48

Fő mutatók
By Trading Economics
Bevétel	-571M -633M
Értékesítés	5.9M 44M
Egy részvényre jutó nyereség	-0.08
Profit margin	-1,431.439
Munkavállalók	684
EBITDA	-569M -600M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+79.31% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 2.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-293M 7.5B
Előző nyitás	5.08
Előző zárás	7.42

Hangulat hírek alapján

By Acuity

50%

156 / 340 Rangsor szerint Healthcare

ImmunityBio Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 5. 19:26 UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

2026. aug. 4. 23:46 UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

2026. aug. 3. 23:21 UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

2026. aug. 1. 00:02 UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

2026. júl. 31. 23:06 UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

2026. júl. 30. 19:29 UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

2026. júl. 29. 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

2026. júl. 28. 20:06 UTC

News

ImmunityBio Inc is under investigation for potential wrongdoing, contributing to its decline today. Shares remain lower since Monday's close, marking six consecutive sessions of losses.

2026. júl. 27. 19:16 UTC

Immunitybio Inc. shares are lower, continuing a four-session decline amid broader market pressures and a significant drop in oil prices.

2026. júl. 24. 23:06 UTC

Immunitybio Inc shares are higher in after-market hours following Friday's close, settling with a cumulative increase after earlier gains. No specific news was identified.

2026. júl. 23. 09:16 UTC

Immunitybio Inc shares are higher in pre-market hours, continuing an upward trend since Wednesday. This movement occurs amid broader market pressures from disappointing tech earnings.

2026. júl. 22. 19:11 UTC

Immunitybio Inc's shares are lower today, diverging from recent gains. The stock is seeing unusually high trading volume amid rising crude oil prices.

2026. júl. 21. 18:06 UTC

Immunitybio Inc is trading higher during Tuesday's session amid positive market sentiment. No specific company news was identified to explain the movement.

2026. júl. 20. 23:46 UTC

Immunitybio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Társak összehasonlítása

Árváltozás

ImmunityBio Inc Előrejelzés

Célár

By TipRanks

79.31% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 13 USD 79.31%

Magas 15 USD

Alacsony 12 USD

3 Wall Street elemző 12 hónapos célárain alapulva a(z)ImmunityBio Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

3 ratings

Vétel

Tartás

Eladás

3 Wall Street elemző célárain alapulva a(z)ImmunityBio Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

156 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.